TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has announced a 1-for-28 reverse stock split, approved on May 2, 2025. The split aims to increase the per share trading price to meet Nasdaq's minimum bid price requirements. This will reduce the number of outstanding shares from 23,341,336 to approximately 833,620. The effective date will be announced at least two business days in advance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.